^
    Back
    Association details:
    Biomarker:CD20 positive
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    RITUXAN (rituximab) is a CD20-directed cytolytic antibody indicated for the treatment of...Adult patients with Non-Hodgkin’s Lymphoma (NHL)...Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent....Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens.
    Secondary therapy:
    CHOP; Chemotherapy
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell lymphoma with CNS localisation

    Excerpt:
    ...CD 20 positive...
    Trial ID:
    2006-002141-37
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab

    Excerpt:
    ...Patients with histological verified CD20-positive B-Cell-Lymphomas of the following entities...
    Trial ID:
    NCT01456351
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    2101 Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL)

    Published date:
    11/04/2020
    Excerpt:
    Multi-institutional Phase II study (NCT01859819). Patients (3-31 years) with CD20+ B-NHL with good risk (FAB Group...Our results demonstrate the feasibility of careful reduction of anthracycline dose intensity with the addition of dose-dense rituximab...Our results demonstrate a 100% EFS/OS with a reduction to only 50mg/m2 total dose of anthracycline.
    Secondary therapy:
    doxorubicin hydrochloride + methotrexate
    Trial ID:
    NCT01859819
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Zhongguo Shi Yan Xue Ye Xue Za Zhi
    Title:

    [Clinical Efficiency of Rituximab Combined with Autologous Hematopoietic Blood Stem Cell Transplantation for Treatment of CD20 + B non.Hodgkin Lymphoma]

    Excerpt:
    ...83 patients with refractory/recurrent CD20+ B.NHL who were treated with auto.HSCT in our department were enrolled. The patients were divided into 2 groups: 57 patients in Rituximab group, and 26 patients in control group(without Rituximab)…. Subgroup analysis showed that: compared with the treatment group in which using R in the whole courses(before and after transplantation, and collection of stem cells) was superior to the control group in both OS and EFS, with the OS 97% vs 87.5% (P>0.05) and EFS 97% vs 76.2% (P=0.05) respectively.
    DOI:
    10.19746/j.cnki.issn.1009-2137.2021.01.013